Vedolizumab

生物活性

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

IC50 & Target

VEGF

体外研究
(In Vitro)

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity,

and inhibits its interaction with VEGFR-1 and VEGFR-2. Experimental analysis shows that the EC50

ofBevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results

that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can

significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p < 0.01)

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

149 kDa(Average)

CAS号

216974-75-3

中文名称

贝伐珠单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.